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Table 1. Outcome Following IV versus IB Xeno-transplantion
Group: IV IB XRT Control Untreated Control P (comparing IV vs. IB)
Median Survival (days) 22 >42 >42 >42 <0.0001
% Surviving at 6 weeks 24% (7/29) 83% (25/30) 100% (10/10) 100% (5/5) <0.0001
Median Hgb at 3 weeks (g/dL) 10.5 (n511) 10.8 (n520) 11.2 (n55) 11.3 (n55) 0.23
Median WBC at 3 weeks (K/uL) 1.46 2.65 1.02 1.16 0.025
Median Plt at 3 weeks (K/uL) 871 1080 930 1443 0.23
Median Human leukocytes (cells/ul) at 3 weeks 67 36 NA NA 0.38
Median % weight change at 3 weeks –13.6% (n516) –6.1% (n530) –5.1% (n510) 0.3% (n55) 0.03
Median Hgb at 6 weeks (g/dL) 9.1 (n57) 10 (n519) 13.1 (n55) 12.7 (n55) 0.12
Median WBC at 6 weeks (K/uL) 0.4 6.78 2.92 2.42 <0.0001
Median Plt at 6 weeks (K/uL) 84 729 986 1270 0.009
Median Human leukocytes (cells/ul) at 6 weeks 178 1005 NA NA 0.0003
Median % weight change at 6 weeks –11.1% (n57) –8.7% (n524) –2.8% (n510) 2.5% (n55) 0.7
Oral Presentations S167strain is an exceptional model for studying xeno-engraftment of hu-
man lympho-hematopoietic cells. We compared survival following
tail-vein (IV) vs. intrafemoral (IB) xeno-transplantation of T-cell
replete G-CSF mobilized human peripheral blood stem cells (G-
PBMNC) into NSG mice.
Methods:NSGmice underwent irradiation with 250 cGy followed 6
hours later by transplantation of 5x106 G-PBMNCs given either IV
(200 mL) or IB (5 mL) under isoflurane anesthesia. Paired mice (IV
vs. IB)were transplantedwith cells froma singledonor.Miceuntreated
or irradiated with 250 cGy that did not receive human cells served as
controls. Following transplantation, mice were weighed weekly and
were phlebotomized tomeasure complete blood counts and to quanti-
tate the % of engrafting human cells by FACS over the 6 week study
period. Necropsy was performed on mice from each group.
Results: Engraftment of human leukocytes was detectable in both
the IB and IV transplant recipients.Median survival was significantly
shorter in IV transplanted mice (22 days) compared to IB trans-
planted mice, where median survival was not reached at 6 weeks (p
\ 0.0001). IV recipients manifested more severe xeno-GVHD
symptoms than IB transplanted mice, losing significantly more
weight and becoming pancytopenic with bone marrows showing se-
vere hypo-cellularity which likely occurred as the consequence of
a graft-versus-murine hematopoiesis effect. In contrast, recipients
of IB transplanted cells did not develop pancytopenia despite having
significantly higher levels of engrafted human cells.
Conclusions: IB xeno-transplantation of humanG-PBMNCs results
in higher degrees of human leukocyte engraftment than IV transplan-
tation while simultaneously protecting the host fromGVHD. In con-
trast, recipients of IV transplantsweremore likely to loseweight and to
develop pancytopenia and marrow aplasia which significantly short-
ened survival compared to IB transplanted mice. These data suggest
the IB route of transplantation should be further studied as a method
to overcome GVHD associated with HLA disparity.42
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We have previously identified five biomarker proteins that have
diagnostic and prognostic value for acute graft-versus-host disease
(GVHD) (Blood 113:273-278, Sci Transl Med 2:50-57). To deter-
mine whether biomarkers can predict GVHD before the appearance
of clinical symptoms, we measured the three most informative bio-
markers (IL2Ra, TNFR1, elafin) by sequential ELISA in patient
samples prospectively obtained prior to conditioning (pre-HCT),
on day17, and day114 after hematopoietic cell transplant (HCT)
from 513 unrelated (URD) HCT patients. We randomly divided
the patients into training (N 5 342) and validation (N 5 171) data
sets that were balanced for (i) full intensity conditioning, (ii) earlyonset of grade II-IV GVHD (\ day121), and (iii) HCT performed
after 2005. We used the training data set to simulate biomarker
values for a hypothetical 50,000 patients using the following assump-
tions: (1) the incidence of GVHD by day 100 is 55%; (2) the median
day of GVHD onset after full intensity URD HCT is day 21, with
10% developing GVHD prior to day17, and 3% after day156.
We used logistic regression to assign each of the 50,000 patients to
low risk and high risk of developing grade II-IV GVHD based
upon the biomarker levels pre-HCT and at day17. We measured
all three biomarkers again in samples taken at day114 in all patients
whowere categorized as low risk and who did not developGVHDby
day114. We determined with another logistic regression model
which low risk patients had now moved to the high risk category.
In the training data set, the combination of these two analyses cor-
rectly predicted the continued absence of grade II-IV GVHD (i.e.
specificity) in 77% (95% CI: 71%-83%) and correctly predicted
the eventual development of GVHD (i.e. sensitivity) in 50% (95%
CI: 42%-58%) of patients. In the validation data set, these tests
gave a specificity of 75% (95% CI: 67%-83%) and a sensitivity of
57% (95% CI: 44%-69%), (Table 1, first row).
Table 1. Sensitivity and Specificity Corresponding to Various
Values of Predicted Probability at Days +7 and +14 Applied to
Validation Data Set
Combined Specificity Combined Sensitivity Correct Prediction of
for both cutpoints for both cutpoints GVHD by Day 5675% 57% 65%
74% 48% 60%
73% 49% 60%
71% 58% 64%
70% 57% 63%The median time between a high risk determination and onset of
grade II-IV GVHD was 14 days. These cutpoints also led to the
greatest correct prediction of GVHD facilitating the design of a trial
to test preemptive treatment of GVHD using these panels. In con-
clusion, measurement of a three-biomarker panel pre-HCT, at
day17, and day114 predicts grade II-IVGVHDwith good specific-
ity (75%) and fair sensitivity (57%).43
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Wehave previously shown that blocking the L-mevalonate pathway
by statins reduces acute graft-versus-host disease (GvHD) in the mu-
rine bone marrow transplanation (BMT) model (Zeiser R et al. Blood
